Press Releases Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Real-time Estimate Cboe BZX Other stock markets 16:43:12 02/05/2024 BST			5-day change	1st Jan Change
23.86 ^USD	+5.39%		+14.83%	+16.04%

04-23	Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target	MT
03-14	Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting	04-22	BU
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04-04	BU
Cartesian Therapeutics Announces New Employment Inducement Grants	04-04	BU
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split	03-28	AQ
Cartesian Therapeutics : Termination of Material Agreement - Form 8-K	03-14	PU
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	03-07	AQ
Cartesian Therapeutics to Participate in Upcoming Investor Conferences	03-06	AQ
Cartesian Therapeutics Announces New Employment Inducement Grant	03-05	AQ
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	03-05	AQ
Cartesian Therapeutics Announces New Employment Inducement Grants	02-05	AQ
Kaskela Law LLC Announces Investigation of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) and Encourages Investors to Contact the Firm	01-18	PR
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity	01-08	AQ
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis	01-08	AQ
Selecta Biosciences Announces Merger with Cartesian Therapeutics	11-13	AQ
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi	31/10/23	AQ
Half-Yearly Report January-June 2023	24/08/23	AQ
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics	17/08/23	AQ
SELECTA BIOSCIENCES INC : Submission of Matters to a Vote of Security Holders (form 8-K)	16/06/23	AQ
Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology	31/05/23	AQ
Interim Report January-March 2023	16/05/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Press Releases

Filters